Obituary

AUB Mourns Professor Emeritus
Anis Baraka

Baraka was awarded the Merit Award Decoration and the Lebanese Citizenship by the President of the Republic of Lebanon in 2000 (in picture Baraka with former Lebanese health minister Karam Karam)

The American University of Beirut mourns the passing away of one of the main founders and pioneers in Anesthesiology in Lebanon and the region, and a longtime colleague and friend of the University, Dr. Anis Baraka.

Professor Emeritus Anis Baraka is an internationally renowned anesthesiologist. He was Professor and Chairman of the Department of Anesthesiology at AUB for more than 30 years (1976-2007), before he was appointed as Professor Emeritus. Dr. Baraka was also Emeritus Editor-In-Chief of the Middle East Journal of Anesthesiology (MEJA). With several international awards and over five hundred publications in areas covering muscle relaxants, obstetric and cardiac anesthesia, as well as anesthesia for children, Dr. Baraka has receive wide international recognition.

He was the Vice-President of the World Federation of Societies of Anesthesiologists and was their representative at the Regional Commission of the United Nations. He was the President of the Arab Board of Anesthesia and Intensive Care as well as the Honorary President of the 8th Pan Arab Congress. He chaired the Committee on Education and Scientific Affairs of the World Federation of Societies of Anesthesiologists and the Examination Committee of the Arab Board of Anesthesia and Intensive Care. He also worked with Arab countries to help establish The Arab Board of Anesthesia and Intensive Care of which he became the Chairman of its Examination Committee.
Born in Fayoum in Egypt in 1930, Dr. Baraka received an MBBCh (Bachelor of Medicine, Bachelor of Surgery) degree in (1953) and completed his residency in 1957 in Anesthesiology at Cairo University. He then did a research fellowship in 1963 at the University of Liverpool and followed it with a residency in 1964 at the National Health Hospital, London.

His long association with AUB started when he joined the University as an Instructor in 1965 and was promoted to an Assistant Professor in 1966, an Associate Professor in 1971, and a full time Professor in 1976. He served as Chairperson of the Department of Anesthesiology for the period of 1976-2007. He was appointed as Professor Emeritus in 2008.

Dr. Baraka served AUB for more than 42 years. The period where he took over the Department of Anesthesiology at AUBMC in 1974 is referred to by his colleagues and department as the “Period of Growth and Development” and “unprecedented excellence”. In a recount of the “HISTORY OF ANESTHESIA IN LEBANON and AT AUB”, authors Fouad Salim Haddad, MD, FAC, DABA Clinical Associate, Department of Anesthesiology, and Musa Khalil Muallem, MD, DA Professor of Anesthesiology, describe Dr. Anis Baraka’s unique contributions. “His warm leadership, pedagogical capabilities, extraordinary ability of clinical research, voluminous publications, fortitude stamina, tenacity and devotion exhibited during the Lebanese civil war, and his worldwide travels, and the various honorary awards he received, doubtless placed the Department of Anesthesiology, the American University of Beirut and Lebanon on the “Anesthesia Map of the World,” they wrote. “Dr. Baraka promoted the prestige of the specialty, increased its market demand, and gained world-wide recognition of the training at his Department.” Dr. Baraka is credited to having shouldered uninterrupted and committed clinical service at operation rooms during the civil war.

A mentor of hundreds of anesthesiologists who lead positions in Lebanon, the region, and abroad today, Dr. Baraka has received recognition for his invaluable and long-standing services and contributions. He was awarded the Merit Award Decoration and the Lebanese Citizenship by the President of the Republic of Lebanon in 2000. He was also awarded the First Rank Education Award from the Ministry of Education in Lebanon in 1990; the First Prize Award of Clinical Medical Sciences at AUB (1987-1988 and 1991-1992); the Shield of the Lebanese Order of Physicians in 1998; the AUB Alumni Association Distinguished Alumni Award in 2006; the Honorary Fellowship of the Royal College of Anesthetists; and the International Commission of the Ralph Waters Prize in 1990.

“Dr. Baraka was a close friend and trusted colleague of my own father, the late Raja Khuri, who always spoke with respect and admiration of the great Anis Baraka’s devotion to his patients, his students, and his field of anesthesia,” said Dr. Fadlo Khuri. “He was a genuine leader in the medical field, not only in Lebanon but in the Arab world and beyond, a gentle man always willing to help others and able to manage the most complicated of cases with grace, with humility, and with great skill... The great Dr. Baraka will be mourned by all who knew him at AUB.”

Dr. Baraka is survived by his wife Aziza, one daughter Huda, and three sons Hesham, Tarek, and Khaled.
BRIDION—For **optimal neuromuscular blockade management** and improved recovery

**Predictable and complete reversal**

- 98% of BRIDION patients recovered to a TOF ratio of 0.9 from reappearance of T1 within 5 minutes
- 97% of BRIDION patients recovered to a TOF ratio of 0.9 from 1 to 2 PTCs within 5 minutes

**Rapid reversal**

- BRIDION rapidly reversed patients from reappearance of T2 in 1.4 minutes
- BRIDION rapidly reversed patients from 1 to 2 PTCs in 2.7 minutes

BRIDION is indicated for the reversal of neuromuscular blockade induced by rocuronium or vecuronium. In children and adolescents (aged 2-17 years), BRIDION is only recommended for routine reversal of moderate rocuronium-induced neuromuscular blockade.

**Important safety information**

BRIDION is not recommended in patients with severe renal impairment. Studies in patients with hepatic impairment have not been conducted and, therefore, patients with severe hepatic impairment should be treated with great caution. Lactation should be exercised when administering BRIDION to pregnant women as no clinical data on exposed pregnancies are available.

BRIDION has not been investigated in patients receiving rocuronium or vecuronium in the intensive care unit (ICU) setting. Physostigmine blockade is required within 24 hours of BRIDION administration, a nonsteriodal neuromuscular blocking agent should be used instead of rocuronium or vecuronium. The most commonly reported adverse reaction were dizziness (tired or drowsy) and anesthetic complications (movement, coughing, stimulating, or sucking on the endotracheal tube). In patients treated with BRIDION, a few cases of awareness were reported. The relation to BRIDION was uncertain. In a few individuals, allergic-like reactions (e.g., flushing, erythematous rash) following BRIDION were reported. Clinicians should be prepared for the possibility of allergic reactions and be ready to manage them.

Voluntary studies have demonstrated a slight (11%-22%) and transient (<34 minutes) prolongation of the prothrombin time/partial thromboplastin time (PT/PTT) with BRIDION; however, clinical studies have demonstrated no clinically relevant effect on post- or postoperative bleeding complications with BRIDION alone or in combination with anticoagulants. As BRIDION has demonstrated an in vitro pharmacodynamic interaction with anticoagulants, caution should be exercised. In patients on anticoagulants for a pre-existing or concomitant condition, this pharmacodynamic interaction is not clinically relevant for patients receiving routine postoperative prophylactic anticoagulation. Although formal interaction studies have not been conducted, no drug interactions were observed in clinical trials. Preclinical data suggest that clinically significant drug interactions are unlikely with the possible exception of terfenadine, hoar, and hormonal contraceptives.

Please see summary of product characteristics for full prescribing information.

**REFERENCES**


Copyright © 2010 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. All rights reserved. 05-2013 BRID-2011-06-1196-J
Pioneering Medical Technology

TAP Block And InfiltraLong
For Effective Treatment Of Long And Deep Incisions

Sono Cannulas
For Single Shot UltraSound Guided Nerve Blocks

SonoSystem And SonoLong Curl
For UltraSound Guided Nerve Blocks

Sprotte 2.G
The New Generation Dura Punctre In Minimum Time

SonoEye Ophtalmic Block
For Peribulbar And Retrobulbar Blocks Under Ultrasonic Monitoring

www.mediline-lb.com Tel:+961 1 697500
Question.
Your patient requires urgent pain medication. How can you administer this less invasively?

Answer.

Atomization spray
The spray atomizes drugs into a fine mist of particles 30-100 microns in size. 1

Malleable stylet
The malleable stylet allows 180° positioning of the nasal plug.

Accurate dosing
The syringe enables the accurate measurement of drugs to be delivered.

Pressure
High applied pressure ensures that drugs are atomized into a fine mist of particles through the tip of the plug.

Soft conical plug
The plug forms a seal with the nasal preventing expulsion of fluid.

Spray geometry
Spray cone with a wide 62.7° average spray angle and a 36.9mm average plume width. 1

References:
2. MAD (Mucosal Atomization Device) Medical Atomizer In Vivo Spray Characterization, 2011
It’s like flying business class and paying coach fare.

In an uncertain world where perioperative care is increasingly complex, uptime is critical. GE’s anesthesia portfolio is known for dependable quality and a commitment to reliable performance that helps reduce operational costs long after the point of purchase. Today, GE Healthcare is changing the game and redefining affordable performance for the masses. No compromises. No boundaries.

Carestation 600 Series...It’s all within reach.

carestation600.com
© 2015 General Electric Company - All rights reserved.
GE and GE Monogram are trademarks of General Electric Company.

C.M.M. S.A.R.L.
SUPPLIES & SERVICES
www.cmm_lb.com
Vanilian Center, Fuad Chehab Ave. Sin El Fil, Beirut, Lebanon
P.O.Box: 166804 T:+961 (01) 512-820 +961 (01) 512-821
M:+961 101 740 F:+961 (01) 512 822